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Clinical Commentary Review
Mechanism-Based Strategies for the Management
of Autoimmunity and Immune Dysregulation in
Primary Immunodeficiencies
Jolan E. Walter, MD, PhDa,b,c, Jocelyn R. Farmer, MD, PhDd, Zsofia Foldvari, MDe,f, Troy R. Torgerson, MD, PhDg, and
Megan A. Cooper, MD, PhDh St Petersburg, Fla; Boston, Mass; Oslo, Norway; Seattle, Wash; and St Louis, Mo
A broad spectrum of autoimmunity is now well described in
patients with primary immunodeﬁciencies (PIDs). Management of
autoimmune disease in the background of PID is particularly
challenging given the seemingly discordant goals of immune
support and immune suppression.Our growing ability todeﬁne the
molecular underpinnings of immune dysregulation has facilitated
novel targeted therapeutics. This review focuses on mechanism-
based treatment strategies for the most common autoimmune and
inﬂammatory complications of PID including autoimmune
cytopenias, rheumatologic disease, and gastrointestinal disease. We
aim to provide guidance regarding the rational use of these agents in
the complex PID patient population.  2016 The Authors.
Published by Elsevier Inc. on behalf of the American Academy of
Allergy,Asthma&Immunology.This is anopenaccess article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/). (J Allergy Clin Immunol Pract 2016;4:1089-100)
Key words: Primary immunodeﬁciencies (PIDs); Treatment;
Autoimmunity; Cytopenias; Arthritis; Vasculitis; Lupus; Autoim-
mune enteropathy (AIE); Inﬂammatory bowel disease (IBD)
Autoimmune and inﬂammatory diseases can complicate the
course of primary immunodeﬁciency (PID) and the complex care
of these patients.1 The clinical spectrum is broad and frequently
includes autoimmune cytopenias, rheumatologic disease, and
gastrointestinal (GI) disease.2,3 The pathogenesis of immune
dysregulation leading to autoimmunity in PIDs was recently
comprehensively reviewed.4 In light of mechanistic understand-
ing, it is timely to review management strategies.
Balancing immunosuppressive therapy in patients with sus-
ceptibility to infection is a clinical challenge. Treatment success
hinges on correcting the underlying immune dysregulation while
minimizing nonspeciﬁc immune suppression. Herein, we will
review the management of PID-associated autoimmunity by
therapeutic mechanism: targeting B-cell, T-cell, or innate
immune pathology or using hematopoietic stem cell trans-
plantation (HSCT) to reconstitute the immune system.
TREATMENT OF AUTOIMMUNE CYTOPENIAS IN
PIDs
Although autoimmune cytopenias, including autoimmune
hemolytic anemia (AIHA), immune thrombocytopenic purpura
(ITP), and autoimmune neutropenia, occur in the general pop-
ulation, they are particularly common in patients with PID. As
an example, PID was uncovered in 13% of children with AIHA5
and up to 50% of children with multilineage cytopenias (Evans
syndrome).6 Autoimmune cytopenias have been described in
both innate and adaptive immune deﬁciencies3,7 and may be the
ﬁrst sign of immune dysregulation that precedes the classical
presentation of PID with recurrent or opportunistic infections.8,9
Clinical warning signs that may prompt the clinician to consider
PID at an earlier stage include multilineage cytopenias, AIHA
with no response to ﬁrst-line therapy, persistent/chronic
ITP, and autoimmune neutropenia in a patient older than 2
years and/or persistent for more than 24 months.10-14
Corticosteroids are the mainstay of treatment for AIHA with a
high response rate around 80% in the general population.15 For ITP,
corticosteroids or high-dose intravenous immunoglobulin (IVIG) are
considered ﬁrst-line therapy.16 In the fraction of patients who relapse
after these therapies, splenectomy has been the traditional second-
line approach. With the advance of biologics, anti-CD20 antibody
(rituximab) is now considered an effective second-line approach
although randomized clinical trials are lacking. In general, clinical
approach in treatment-resistant cases is one of therapeutic trial and
error in the absence of a guiding underlying immunophenotype or
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Abbreviations used
AIE- Autoimmune enteropathy
AIHA- Autoimmune hemolytic anemia
ALPS- Autoimmune lymphoproliferative syndrome
BAFF- B-celleactivating factor
CGD- Chronic granulomatous disease
CID- Combined immunodeﬁciency
CTLA4- Cytotoxic T-lymphocyte antigen 4
CID- Combined immunodeﬁciency
CVID- Common variable immunodeﬁciency
GI- Gastrointestinal
GOF- Gain-of-function
HSCT- Hematopoietic stem cell transplantation
IBD- Inﬂammatory bowel disease
IPEX- Immune dysregulation polyendocrinopathy enteropathy
X-linked syndrome
ITP- Immune thrombocytopenic purpura
IVIG- Intravenous immunoglobulin
JIA- Juvenile idiopathic arthritis
LRBA- LPS-responsive vesicle trafﬁcking, beach and anchor
containing protein
PID- Primary immunodeﬁciency
RAG- Recombination activating gene
SCID- Severe combined immunodeﬁciency
SLE- Systemic lupus erythematosus
STAT- Signal transducer and activator of transcription
Treg- Regulatory T cell
biomarkers to direct care. In contrast, second-line treatment
strategies for PID-associated autoimmune cytopenias are
increasingly being targeted to the underlying mechanism of
immunopathology.
Targeting B-cell pathology
Several studies address the approach to autoimmune cytope-
nias in the background of common variable immunodeﬁciency
(CVID), a heterogeneous condition deﬁned by decreased serum
immunoglobulin levels (low IgG level with low IgM and/or IgA
level), frequent infections, and poor antigen-speciﬁc antibody
titers.17 Classical CVID is considered to be a primary disorder of
B cells. However, improved genetic discovery and immunophe-
notyping has led to reclassiﬁcation of a growing CVID subset as
de facto combined immunodeﬁciency (CID).18
The link between CVID and autoimmunity was ﬁrst estab-
lished in the 1990s19 and has been greatly expanded since that
time (Table I).20,21 Initial treatment regimens for autoimmune
cytopenias included combinations of corticosteroids, high-dose
IVIG, and anti-Rho(D) in the case of ITP. These guidelines
were extrapolated from the standard of care in the general pop-
ulation. Initial response rates to corticosteroids were reasonable,
85% for ITP56 and 81% for AIHA57; however, prolonged use
was often required, which increased the risk for infection as a
secondary complication. Before the era of biologics, nearly half of
these autoimmune cytopenia cases ultimately required second-
line splenectomy (response rates of 60%-80%), which was in
contrast to the majority of ﬁrst-line treatment responders seen in
the general population.8,56,57 Other agents such as vinca-
alkaloids, danazol, cyclophosphamide, azathioprine, and cyclo-
sporine did not show long-term success and are now rarely used.
In 2004, rituximab was introduced as second-line therapy for
CVID-associated AIHA.58 In a subsequent multicenter study of
33 patients with CVID with refractory autoimmune cytopenias,
which included steroid dependence (56%), immunomodulatory
therapy (44%), and previous splenectomy (21%), rituximab
was demonstrated to have a durable response rate of 59%.59
The authors proposed that rituximab be considered standard
second-line therapy, before splenectomy and/or other immuno-
modulatory therapy, in CVID-associated autoimmune cytope-
nias. Although 24% of patients developed severe bacterial
infections after rituximab treatment, half of these cases were off
immunoglobulin replacement therapy and/or had undergone
splenectomy.59 Although a matter of concern, the rate of severe
bacterial infections was not signiﬁcantly different than that
observed in patients with CVID with ITP treated by the more
traditional approach of corticosteroids with or without high-dose
IVIG.56 Therefore, the risk for infection with rituximab use
needs to be considered primarily in patients with CVID not
receiving immunoglobulin replacement therapy.
Response to B-cell depletion therapy in most cases of CVID-
associated autoimmune cytopenias localized the immunopa-
thology to the B-cell compartment and suggested that other thera-
pies targeting this compartmentmay also be efﬁcacious. It should be
emphasized that rituximab depletes only maturing B cells and does
not target long-lived plasma cells that can sustain autoantibody
production in lymphoid niches for some time (months) after
treatment. Alternative B- celledirected therapy may include bor-
tezomib, a proteasome inhibitor that is approved for the treatment of
multiple myeloma and preferentially causes apoptosis of antibody-
producing plasma cells through activation of the unfolded protein
response.60 Bortezomib has shown promising results in peritrans-
plant cases of PID-associated refractory autoimmune cytopenias
speciﬁcally (4 of 5 patients with PID responded to treatment and
only 2 patients required transition to alternative therapy61). Addi-
tional B-celledirected therapies currently in clinical trial include an
anti-CD22 antibody (epratuzumab) and an anti-APRIL antibody.
Both show promise in severe refractory autoimmune diseases
including cytopenias,62-65 but are yet to be trialed in PID specif-
ically. Finally, the terminal complement inhibitor eculizumab (anti-
C5) has been used to rescue a patient from fatal complications
related to treatment-refractory AIHA.66 Because it acts distal to the
B cell in autoantibody-mediated diseases, it could in theory be
applied in combination with B-celledepleting therapies to more
completely control disease. The mechanism of action for these
biologics is reviewed in Figure 1.
Targeting T-cell pathology
Patients with PID with prominent T-cell dysfunction may not
fully beneﬁt from the removal of autoreactive B cells. In auto-
immune lymphoproliferative syndrome (ALPS), the accumula-
tion of pathognomonic TCRabþCD4CD8 (double-negative)
T cells occurs secondary to defective apoptosis. Although auto-
immune cytopenias are a key feature of the disease (Table I),
rituximab is a therapy of last resort given the associated ﬁnding of
profound and prolonged hypogammaglobulinemia up to 4 years
posttreatment.67 Similarly, splenectomy is less preferred because
it may result in unfavorable outcomes with recurrent cytopenias
and high rates of sepsis (41%) in patients with ALPS.30
The conventional ﬁrst-line therapy for ALPS-associated auto-
immune cytopenias has been corticosteroids, but second-line
therapies including mycophenolate mofetil (a prodrug of myco-
phenolic acid that inhibits inosine monophosphate dehydrogenase
and suppresses T and B cells) and sirolimus (an mTOR inhibitor)
that more effectively target double-negative T cells are increasingly
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TABLE I. PIDs associated with autoimmune disease
PID Immunologic defect
AI cytopenias
prevalence (%)
Rheum disease
prevalence (%)
GI disease prevalence
(%)
Other noninfectious
manifestations References
CVID Polygenic
Low IgG (low IgA or IgM),
low vaccine titers, low sm
B cells, high CD19hi21lo B
cells
ITP (5.6-14.2)
AIHA (2.7-7)
AN (<1-2.7)
Evans (4.2)
RA (3.2)
Vasculitis & SLE
(<1-2.7)
Diarrhea (14-23)
Malabsorption/AIE
(6-9)
IBD (4.2)
Lymphoproliferative
pathology (LAD, HSM,
GLILD, NRH, leukemia,
lymphoma)
Other autoimmunity
(hepatitis, alopecia,
thyroiditis, vitiligo)
20-24
XLA BTK
Low/absent circulating B
cells, loss of germinal
centers, pan low
immunoglobulins,
impaired innate immune
signaling, decreased Tfh
cells
ITP (2.7*)
AIHA (9.8*)
RA/JIA (1.8*-16) Diarrhea (8*-29)
IBD (3.6*-3.8)
Neutropenia in the setting of
overwhelming infection
25-29
ALPS TNFRSF6 (FAS), TNFSF6
(FASL), CASP10
High DN T cells, IL-10,
IL-18, vitamin B12, FAS;
decreased FAS-mediated
apoptosis
ITP (26-39)
AIHA (29-36)
AN (8-37)
Evans (10-23)
Uveitis (1-10)
Vasculitis (4)
Arthritis (case
reported)
IBD (case reported) Lymphoproliferative
pathology (LAD, HSM,
lymphoma)
Other autoimmunity
(hepatitis, PBC, GBS, GN)
30-35
pDGS 22q11.2
Impaired thymic
development, decreased
T-cell number & function,
variably decreased IgG/A/
M & sm B cells
ITP (3.1-6.3)
AIHA (0.5-3.1)
Evans (0.5-3.1)
Vasculitis (3.1)
Arthritis (2.5-3.1)
IBD (0.5) Craniofacial anomalies,
hypoplastic thymus,
conotruncal cardiac
anomalies, hypocalcemia
Other autoimmunity
(thyroiditis)
36-39
CTLA4 CTLA4 (haploinsuﬁciency)
Impaired FOXP3þ Treg
cells, activated effector &
decreased naive T cells,
low IgG, low B cells, high
CD21lo B cells
ITP (35)
AIHA (28)
Arthritis (14) Diarrhea/AIE (78) Lymphoproliferative
pathology (LAD, HSM,
GLILD)
Other autoimmunity
(thyroiditis)
40-42
LRBA LRBA
Decreased/impaired
FOXP3þ Treg cells,
activated T effector cells,
low IgG, low B cells (sm
B cells and plasmablasts)
ITP (29-52)
AIHA (39-57)
AN (24)
Arthritis (26)
Uveitis (10)
Diarrhea/AIE (61-62) Growth retardation, eczema
Lymphoproliferative
pathology (LAD, HSM,
GLILD, lymphoma)
Other autoimmunity (T1DM,
thyroiditis, hepatitis,
alopecia)
43-45
IPEX FOXP3
Impaired FOXP3þ Treg
cells, high IgE, high
eosinophils, low TH1
cytokines, high TH2
cytokines
AIHA or ITP or
AN (31)
Arthritis (1) Diarrhea/AIE (92) FTT, severe dermatitis
Lymphoproliferative
pathology (LAD, HSM)
Other autoimmunity (early-
onset T1DM, thyroiditis,
hepatitis)
46
STAT3-GOF STAT3
Decreased/impaired
FOXP3þ Treg cells,
increased DN T cells,
variably low IgG
ITP (62)
AIHA (69)
AN (46)
Evans (46)
Arthritis (15-20) AIE (38-60) Short stature, eczema
Lymphoproliferative
pathology (LAD, HSM,
GLILD, lymphoma)
Other autoimmunity (T1DM,
thyroiditis, alopecia,
scleroderma, hepatitis)
47,48
STAT1-GOF STAT1
Augmented TH1, decreased/
impaired TH17, low
memory B cells, low IgG2/
IgG4
AIHA or ITP (4) SLE (2) AIE (4) Aneurysms, eczema,
carcinomas
Other autoimunity
(thyroiditis, T1DM,
alopecia, vitiligo,
psoriasis, hepatitis)
49,50
(continued)
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being used as primary therapy.68,69 Sirolimus was ﬁrst trialed in 4
corticosteroid-refractory patients with ALPS in 2009 and resulted
in marked improvements in both autoimmune cytopenias and
associated systemic inﬂammatory features (arthritis, colitis,
lymphadenopathy, and splenomegaly).10 In a subsequent trial of
30 patients with refractory autoimmune cytopenias acrossmultiple
PIDs (CVID and ALPS), sirolimus resulted in a complete and
durable remission inmost patients.70 Treatment response in ALPS
has been shown to coincide with a speciﬁc reduction in double-
negative T cells, which are particularly dependent on an intact
mTOR pathway.70-73
Autoimmune cytopenias have been associated with partial
DiGeorge syndrome, occasionally preceding diagnosis of the
underlying genetic defect (Table I).74-76 Breaks in both central
T-cell tolerance (eg, thymic aplasia/dysplasia) and peripheral T-
cell tolerance (eg, T-cell proliferation to low-afﬁnity self-
antigens) have been proposed to induce autoimmunity.36 To
date, large studies do not exist as to the optimal therapeutic
approach. Steroids and azathioprine have been anecdotally used
to treat ITP with beneﬁt.75 Progression despite rituximab has
been reported in 2 cases of severe autoimmune cytopenias
associated with partial DiGeorge syndrome, one requiring HSCT
for deﬁnitive treatment77 and the other requiring plasmaphoresis
in combination with splenectomy for stabilization.78
Autoimmune cytopenias can also occur in the setting of regu-
latory T-cell (Treg) dysfunction. Cytotoxic T-lymphocyte antigen
4 (CTLA4) haploinsufﬁciency is a novel autosomal-dominant
immunodeﬁciency in which decreased CTLA4 cell surface
expression results in impaired Treg-cell suppressor function. It has
been associated with a broad clinical spectrum of autoimmunity
including high rates of ITP and AIHA (Table I). Here, direct
complementation of the underlying immunoregulatory defect
TABLE I. (Continued)
PID Immunologic defect
AI cytopenias
prevalence (%)
Rheum disease
prevalence (%)
GI disease prevalence
(%)
Other noninfectious
manifestations References
WAS WAS
Decreased T-cell number &
function, low IgG/A/M,
high IgE, low vaccine
titers
ITP (32)
AIHA (14-36)
Evans (20)
Vasculitis (13)
Arthritis (10)
IBD (3) Microthrombocytes with low
count & poor function,
eczema, mucosal bleeding,
lymphoma, renal disease
51
CGD CYBB (x), CYBA, NCF1,
NCF2, NCF4
Dysfunctional NADPH
oxidase, impaired
phagocytosis, aseptic
hyperinﬂammation
ITP (1.4) DLE (2.7)
Chorioretinitis
(2.2)
SLE, APLS,
vasculitis, &
arthritis (<1)
IBD (17-88) Lymphoproliferative
pathology with severe
multiorgan granulomatous
disease (GI tract, lungs,
kidneys, eyes)
52-55
AI, Autoimmune; AN, autoimmune neutropenia; APLS, antiphospholipid syndrome; DLE, discoid lupus erythematosus; DN, double negative; FTT, failure to thrive; GBS,
Guillain-Barre syndrome; GLILD, granulomatous and lymphocytic interstitial lung disease; GN, glomerulonephritis; HSM, hepatosplenomegaly; LAD, lymphadenopathy; MG,
myasthenia gravis; NADPH, nicotinamide adenine dinucleotide phosphate; NRH, nodular regenerative hyperplasia; PBC, primary biliary cirrhosis; pDGS, partial DiGeorge
syndrome; PID, primary immunodeﬁciency; RA, rheumatoid arthritis; rheum, rheumatologic; sm, switched memory; T1DM, type 1 diabetes mellitus; Tfh, follicular helper T cell;
WAS, Wiskott-Aldrich syndrome; XLA, x-linked agammaglobulinemia.
*Patient self-reported.
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FIGURE 1. Mechanisms of targeting B-cell pathology in the treatment of autoimmune and inflammatory diseases associated with PID.
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with CTLA4-immunoglobulin (abatacept) has been anecdotally
reported to treat pancytopenia and associated life-threatening
autoimmunity otherwise refractory to corticosteroids,
tacrolimus, azathioprine, cyclophosphamide, and sirolimus.40
LPS-responsive vesicle trafﬁcking, beach and anchor containing
protein (LRBA) deﬁciency is an associated autosomal-recessive
TABLE II. CIDs associated with autoimmune cytopenias
Gene Function
Autoimmune
cytopenias Treatment strategies Associated autoimmunity References
RAG1, RAG2 dsDNA cleavage during
V(D)J recombination
AIHA, ITP, AN Steroids, IVIG, rituximab,
HSCT
Vasculitis, GBS, MG,
psoriasis, vitiligo
92,98,99
DCLRE1
(ARTEMIS)
Nonhomologous end joining,
opening the hairpins
AIHA, ITP, AN NA 100,101
ADA Deamination of adenosine
and 20-deoxyadenosine
AIHA, ITP PEG-ADA, HSCT AI thyroiditis, T1DM 102
PNP Conversion of inosine and
guanosine to hypoxanthine
AIHA, ITP Steroids, rituximab,
azathioprine, cyclosporine,
HSCT
103
RMRP RNA component of the
mitochondrial RNA
processing (RMRP)
endoribonuclease complex
AIHA, ITP
post-HSCT
Steroids, IVIG, rituximab,
HSCT
Granulomas 104
TRAC Loss of TCR
(transmembrane &
intracytoplasmic domains)
AIHA Treatment is not discussed,
s/p HSCT
Vitiligo, alopecia areata,
pityriasis rubra pilaris
105
IL-7R Signaling through the IL-7
receptor ensures the
development of mature B
cells & T cells
AIHA, ITP Treatment is not discussed,
s/p HSCT
106
CD3ɣ TCR signal transduction AIHA, ITP Steroids AI hepatitis & thyroiditis,
minimal change disease
107
ZAP70 CD3z binding, T-cell
activation
ITP IVIG Arthritis, nephritis in the
mouse model
108
LCK/p56 TCR signaling, associated
with CD4 and CD8, upon
activation mediates
phosphorylation of CD3
and ZAP70
ITP Steroids, HSCT Retinal vasculitis, sterile
septal and lobular
neutrophillic panniculitis,
sterile arthritis
109
MST1/STK4 Interacts with Foxo1 that
controls IL-7Ra
expression in naive T cells
and T-cell homeostasis
AIHA, ITP, AN Steroids, IVIG, rituximab,
cyclosporine, azathioprine
110-112
ORAI1
(CRACM1)
Store-operated calcium entry,
interaction with STIM1,
T-cell activation
ITP, AN NA 113
STIM1 ER-resident calcium sensor,
activates ORAI1 to
promote store-operated
calcium entry
AIHA, ITP Steroids 114
MAGT1 Magnesium-speciﬁc
transporter and immune
regulator
Unspeciﬁed
cytopenias
NA 115
PIK3CD
(PI3K-D)
Akt-mTOR pathway
activation, generation of
short-lived effector CD8þ
cells
AIHA, ITP NA 116,117
TPP2 Cell proliferation and
survival, antiapoptotic
AIHA, ITP Steroids, IVIG, cyclosporine,
MMF, rituximab,
sirolimus, HSCT
118
DOCK8 Intracellular signal
transduction
AIHA NA Thyroiditis 119-122
MHCII Antigen presentation Unspeciﬁed
cytopenias
NA 7,123
AI, Autoimmune; AN, autoimmune neutropenia; ER, endoplasmic reticulum; GBS, Guillain-Barre syndrome; MG, myasthenia gravis; MMF, mycophenolate mofetil; NA, not
annotated; T1DM, type 1 diabetes mellitus; TCR, T-cell receptor.
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PID in which Treg-cell impairment occurs secondary to aberrant
recycling of CTLA4 to the cell surface.43 It is strongly associated
with systemic autoimmunity including cytopenias (Table I). Ma-
jor treatment modalities have included corticosteroids (39%),
IVIG (39%), mycophenolate mofetil (22%), abatacept (15%),
tacrolimus/sirolimus (11%), and HSCT (11%).44 Interestingly,
inhibition of lysosomal degradation via chloroquine/hydroxy-
chloroquine rescued CTLA4 expression in LRBA-deﬁcient cells
in vitro43 and improved lymphoproliferative lung pathology in a
patient with LRBA mutation in vivo79; however, improvement in
autoimmune cytopenias speciﬁcally is yet to be described.
Finally, patients with signal transducer and activator of tran-
scription (STAT)1-gain-of-function (GOF) mutations develop
chronic mucocutaneous candidiasis and autoimmunity including
cytopenias in the background of prominent T-cell dysregulation
(Table I). Speciﬁcally, naive CD4þ T cells are uniquely biased
toward IFN-g production irrespective of polarizing conditions and
expansion of follicular helper T cells relative to Treg cells has been
shown.80 T-cell targeting with cyclosporine has been anecdotally
used to treat AIHA in STAT1-GOFwith beneﬁt.81More recently,
a janus kinase 1/2 inhibitor (ruxolitinib) was used to treat 2 distinct
cases of STAT1-GOF with associated autoimmunity including
autoimmune cytopenias80 and refractory alopecia areata.82 Rux-
olitinib was shown to reduce hyperresponsiveness to IFN-g,
restore TH17 and Treg-cell counts, induce long-lasting control of
autoimmunity (up to 6 months posttreatment82), and had the
unexpected beneﬁt of reducing the occurrence of mucocutaneous
candidiasis in both cases.
Immune reconstitution
Patients with severe immunodeﬁciency may require progres-
sion to HSCT for deﬁnitive treatment. Wiskott-Aldrich syn-
drome is a well-described PID in which autoimmune cytopenias
occur beyond abnormal platelet number, size, and function.83
AIHA is severe, early-onset, and poorly responsive to cortico-
steroids, and ITP mainly occurs postsplenectomy (Table I). The
presence of autoimmunity increases disease severity and con-
tributes to the indication for HSCT. Unfortunately, even after
HSCT and/or gene therapy autoimmune cytopenias may resur-
face and become refractory,84-87 as demonstrated by the 55% of
patients with Wiskott-Aldrich syndrome who developed auto-
immune cytopenias in the posttransplant period.88 Thrombo-
poietin receptor agonists such as romiplostim and eltrombopag
are emerging therapies for ITP, mainly by promoting platelet
production. Because these agents are not immunosuppressive,
they could be particularly useful in the treatment of ITP on a
background of PID going forward.89-91
Finally, autoimmunity is increasingly recognized among pa-
tients with CIDs secondary to classical severe combined immu-
nodeﬁciency (SCID)-related gene defects. Patients with
recombination activating gene (RAG) mutations can have broad
clinical heterogeneity ranging from early-onset severe infections
(SCID phenotype) to delayed-onset autoimmune and inﬂam-
matory complications such as cytopenias, vasculitis, and granu-
lomas (CID-AI/G phenotype).92 Speciﬁc RAG mutation, RAG
activity, and ultimately the resultant B- and T-cell repertoire
correlate well with these distinct phenotypes.93 Several check-
points of B- and T-cell tolerance are impaired in RAG deﬁciency,
which results in impaired removal of autoreactive cells (abnormal
thymic selection, dysfunctional Treg cells, impaired B-cell
receptor editing in the bone marrow, and elevated
B-celleactivating factor [BAFF] expression).94-96 However, the
relative contribution of these mechanisms in driving autoim-
munity is still unclear. Treatment outcomes data in our RAG-
deﬁcient cohort suggest that second-line therapy with biologics
is not standardized and often ineffective. Progression to HSCT
for deﬁnitive treatment was ultimately required in 20% of pa-
tients with CID-AI/G with autoimmune cytopenias.97
Autoimmune cytopenias have been anecdotally reported in
other CIDs (PIK3CD [PI3K-D], TPP2, andDOCK8) as well as in
hypomorphic SCID variants (DCLRE1 [ARTEMIS], ADA, PNP,
RMRP, andORAI1)91 (Table II). The largest review to date details
14 hypomorphic ARTEMIS cases, where 6 of 14 patients (45%)
had autoimmune cytopenias.100 For the other PIDs in this group,
autoimmune cytopenias are more sporadically reported and
treatment strategies have not been discussed in depth.
TREATMENT OF RHEUMATOLOGIC DISEASE IN
PIDs
PIDs are now known to be associated with a spectrum of rheu-
matologic disease including inﬂammatory arthritis, vasculitis, sys-
temic lupus erythematosus (SLE), and SLE-like disorders (Table I).
It is not uncommon that rheumatologic disease is treated before the
discovery of an underlying PID, which can result in substantial in-
fectious complications. Indeed, delay in immunophenotyping and
deﬁnitive treatment has resulted in increased morbidity and/or fatal
outcomes in cases recently reported.98,124,125 Therefore, clinicians
must consider the risk for infection when approaching therapeutic
options for rheumatologic disease in PID. Here, we discuss PID-
associated rheumatologic diseases with polyautoimmunity. There
are a signiﬁcant number of important PIDs that cause primarily
rheumatologic disease, for example, complement deﬁciencies and
monogenic disorders of dysregulated IL-1 production, which have
been reviewed elsewhere.126-128
Targeting B-cell pathology
CVID has been associated with rheumatologic complications
including inﬂammatory arthritis, vasculitis, and SLE (Table I).
Most patients will require therapy beyond IVIG. Case reports
have demonstrated successful use of rituximab to treat both
CVID-associated SLE129 and ANCA-positive vasculitis.130 These
data localize pathology to the B-cell compartment and suggest
that other B-celletargeting strategies may be efﬁcacious. Beli-
mumab is a novel therapeutic uniquely targeting BAFF that just
gained Food and Drug Administration approval for the treat-
ment of SLE.131 Rationale for its use originated in the notion
that autoreactive B cells have less BAFF-R on their surface and
reside in an anergic state when BAFF levels are normal.132 In
inﬂammatory conditions, BAFF levels may elevate and
contribute to the survival of autoreactive cells.133 Although
promising, belimumab is yet to be trialed in CVID speciﬁcally
and may need special consideration in patients with BAFF re-
ceptor deﬁciencies (TACI and BAFF-R). Other potential
mechanisms of targeting B-cell pathology that may prove efﬁ-
cacious in CVID-associated rheumatologic disease have already
been reviewed (Figure 1).
Targeting T-cell pathology
The predominance of rheumatologic complications seen in
patients with Treg-cell dysfunction including CTLA4 hap-
loinsufﬁciency, LRBA deﬁciency, and STAT3-GOF (Table I)
converges on the hypothesis that FOXP3þCD25þCD4þ Treg
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cells play a critical role in host defense against the development of
rheumatologic diseases including inﬂammatory arthritis.134
Consistent with this hypothesis, CTLA4-immunoglobulin ther-
apy (abatacept) is approved by the Food and Drug Administration
for the treatment of rheumatoid arthritis and juvenile idiopathic
arthritis (JIA) in the general population. More recently, abatacept
has shown beneﬁt in PID. In LRBA deﬁciency, 2 children with
inﬂammatory arthritis and uveitis (clinically consistent with JIA)
demonstrated robust response to abatacept therapy.43,135 In-
ﬂammatory arthritis can also complicate the course of CTLA4
haploinsufﬁciency,41 and it is yet to be determined whether
abatacept will be additionally beneﬁcial in these cases. Finally,
inﬂammatory arthritis has been reported in several patients with
STAT3-GOF.47,48 Immunophenotype is notable for decreased
Treg-cell numbers and functional expression of FOXP3 and
CD25, potentially mediated by increased STAT3-dependent
SOCS3 expression driving decreased STAT5 phosphoryla-
tion.47,48 Because Treg-cell inhibition in STAT3-GOF is indirect,
clinicians hypothesized that the use of an anti-IL6R antibody
(tocilizumab) might be beneﬁcial via blocking upstream IL-
6einduced STAT3 activation. To date, 1 patient with STAT3-
GOF complicated by arthritis and scleroderma-like skin changes
refractory to treatment with TNF-a inhibitors, antieIL-1 ther-
apy, and rituximab demonstrated sustained response to tocilizu-
mab over a 1-year follow-up period.47
Inﬂammatory arthritis is also a known complication of
x-linked agammaglobulinemia, a PID in which autoreactive B
cells are effectively absent because of maturation arrest at the
preeB-cell stage. Although infectious joint inﬂammation
resolving on immunoglobulin replacement therapy is frequently
seen in x-linked agammaglobulinemia,25 aseptic arthritis has also
been described including presentations of rheumatoid
arthritis,136 JIA,137,138 and enthesitis-related arthritis.139 Inﬁl-
trating CD8þ T cells can be seen on joint cytology.137 Under-
lying mechanisms of T-celledriven autoimmunity139 and/or
innate immune hyperactivation140,141 have been proposed. In
these cases, IVIG alone can be insufﬁcient management,136,139
progression despite methotrexate has been described,136
nonsteroidal anti-inﬂammatory drugs may provide some
beneﬁt,138,139 and there is no systematic guidance for the use of
T-celle or innate immune-targeted strategies to date.
Targeting innate immune pathology
In contrast to the PIDs previously presented, patients with
chronic granulomatous disease (CGD) develop systemic auto-
immunity in the background of a primary innate immune deﬁ-
ciency. Here, decreased nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase results in defective phagocytosis.
Profound aseptic hyperinﬂammatory responses are seen in CGD,
characterized by loss of anti-inﬂammatory mediators,142
impaired clearance of apoptotic cells,143 and downstream
CD4þ T-cell skewing, which can drive autoimmune arthritis in
the mouse model.144 In patients, CGD has been associated with
cutaneous discoid lupus erythematosus, chorioretinitis, inﬂam-
matory arthritis, vasculitis, and SLE as well as discoid lupus er-
ythematosus in female carriers of x-linked disease
(Table I).52,53,145,146 A single case series on treatment of rheu-
matologic manifestations in CGD recently demonstrated clinical
stabilization with systemic corticosteroids (1 case of discoid lupus
erythematosus), methotrexate (1 case of antiphospholipid syn-
drome), and etanercept (1 case of JIA).52 Although these
anecdotal data are promising, antieTNF-a therapies have been
associated with invasive fungal disease even in immunocompe-
tent hosts and should be used cautiously in these and other
patients with PID with signiﬁcant susceptibility to infection.
Immune reconstitution
HSCT has the potential to be curative for PID with auto-
immunity in terms of reconstitution of the immune system and
reduced susceptibility to infection. However, autoimmune dis-
ease can sometimes persist or even broaden posttransplant. A
total of 70% of patients with Wiskott-Aldrich syndrome have
associated autoimmunity, which can include inﬂammatory
arthritis and vasculitis (Table I). Although arthritis and vasculitis
generally improve after HSCT or gene therapy, there are
several cases where autoimmunity has persisted or even newly
arisen.85-87 RAG deﬁciency has also been associated with rheu-
matologic and autoimmune diseases including vitiligo, myas-
thenia gravis, and vasculitis (Table II).92 Progression of vasculitis
in RAG deﬁciency despite treatment with corticosteroids, IVIG,
and rituximab has been described.98 In contrast, HSCT in RAG
deﬁciency has been case reported to be curative/preventative for
polyautoimmunity.98,147 Because fewer posttransplant auto-
inﬂammatory complications were observed in patients with RAG
deﬁciency compared with patients with impaired ARTEMIS,148
the beneﬁt of HSCT may be PID-speciﬁc. However, additional
clinical evidence is required to determine whether HSCT is truly
curative for rheumatologic disease in PID. Optimal timing for
transplantation, regimen for conditioning, and goal for donor
chimerism are yet to be determined.
TREATMENT OF GI DISEASE IN PIDs
PIDs have been associated with a broad clinical spectrum of
autoimmune GI disorders including gastritis (pernicious ane-
mia), celiac disease, autoimmune enteropathy (AIE), and in-
ﬂammatory bowel disease (IBD) (Table I).149 In the background
of frequent infections (eg, Giardia, Campylobacter, Salmonella,
rotavirus, enterovirus, and norovirus), diagnosis of nonspeciﬁc
GI symptoms such as nausea, vomiting, diarrhea, and weight loss
becomes particularly challenging. However, elucidating the un-
derlying pathophysiology is critical given the associated ﬁnding
of increased mortality in the PID subgroup with GI complica-
tions speciﬁcally.20
Targeting T-cell pathology
Gastritis, AIE, and IBD have all been described in CVID.150
Small intestinal biopsy frequently demonstrates villous atrophy
that resembles sprue apart from the absence of plasma
cells.151,152 Lymphocytic inﬁltrates and occasional granulomas
can occur both in the small intestine and in the colon, consisting
predominantly of CD8þ T cells.151-153 Unfortunately, GI in-
ﬂammatory disease in CVID has been notoriously difﬁcult to
treat. Despite beneﬁt from combination rituximab/azathioprine
therapy to manage granulomatous lung pathology,154 a similar
response has not been seen in the inﬂamed GI tract.155 TNF-a
inhibitors156,157 as well as the anti-a4b7 integrin monoclonal
vedolizumab, which may inhibit Treg-cell trafﬁcking to the GI
mucosa,150 have been anecdotally reported as successful. We
have a case of severe CVID-associated AIE with negative genetic
testing for CTLA4 and LRBA mutations currently improving
after 4 months of treatment with abatacept (weight gain,
decreased stool output, decreased inﬁltrating T cells on biopsy)
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(J.E. Walter and J.R. Farmer, unpublished data). Therefore, GI
inﬂammatory disease may be a unique complication of CVID
where B-cell targeting is insufﬁcient and directed T-cell targeting
is required to effectively manage this often life-threatening
complication.
Mounting data are converging on the importance of Treg cells
in host defense against autoinﬂammation in the GI tract.
Immune dysregulation polyendocrinopathy enteropathy
X-linked syndrome (IPEX) is a profound disorder of
FOXP3þCD25þCD4þ Treg cells caused by mutations in
FOXP3. The pathognomonic clinical features of IPEX are severe
and early-onset dermatitis, type 1 diabetes mellitus, and failure to
thrive secondary to refractory diarrhea starting in infancy.158,159
A demonstrated break in peripheral B-cell tolerance leading to
the production of autoantibodies to the brush border proteins
villin and AIE-75 has been described.160,161 However, the role of
antivillin and antieAIE-75 in disease pathogenesis is entirely
unclear. AIE on biopsy is characterized by villous atrophy with
inﬁltrating lymphocytes and eosinophils. Histopathologic pat-
terns of “graft-versus-host disease-like,” “celiac disease-like,” and
“depletion of the intestinal goblet cells” have all been
described.162 Most single targeted immunosuppressive agents
have been disappointing in the management of the profound
autoimmunity and failure to thrive. However, T-celletargeted
therapeutics including tacrolimus, cyclosporine, and sirolimus
have shown beneﬁt in reducing the burden of IPEX-related
autoimmune disease in the pretransplant period.163-165
Beyond intrinsic Treg-cell defects secondary to abnormal
FOXP3, CD25, or STAT5b, interestingly, AIE and IBD are
shared complications of other Treg-cell disorders including
CTLA4 haploinsufﬁciency,41,42 LBRA deﬁciency,166 STAT1-
GOF,167 STAT3-GOF,47 as well as mutated RAG1,168
DOCK8,169 and ITCH.170,171 Furthermore, autoimmune GI
disease can be robustly induced (27%-54% symptomatic with
watery diarrhea) on treatment with anti-CTLA4 biologics.172
These data again converge on the hypothesis that Treg cells are
critical in gut homeostasis.173 To this end, inﬁltrating T cells have
been demonstrated on intestinal biopsy in CTLA4 hap-
loinsufﬁciency,41 and lack of response to traditional therapeutics
including TNF-a inhibitors has been demonstrated in LBRA
deﬁciency.166 In contrast, sirolimus has been reliably efﬁcacious in
CTLA4 haploinsufﬁcient patients, and immune reconstitution
with abatacept has been shown to markedly reduce AIE.40
Targeting innate immune pathology
Profound autoimmune GI disease can also occur in the setting
of innate immune deﬁciency. Classic is CGD, where multiorgan
granulomatous inﬂammatory pathology occurs, most promi-
nently affecting the GI tract in up to 73% to 88% of patients
(Table I).54,174 Biopsy demonstrates skip lesions most frequently
affecting the ano-rectum and consisting of crypt abscesses, large
pigment-containing macrophages, and noncaseating granulomas,
which can be indistinguishable from Crohn disease.54,174-176
Despite the predisposition toward infection, no causative
pathogens were identiﬁed in up to 93% of CGD-associated in-
ﬂammatory GI disease cases,54 suggesting an underlying mech-
anism of aseptic autoimmunity. Treatment outcomes to date
demonstrate limited beneﬁt from corticosteroids (63%-86%
relapse rate) and/or nonsteroidal anti-inﬂammatory drugs (50%-
100% relapse rate).54 Immunomodulation with methotrexate,
azathioprine, cyclosporine, and thalidomide has been case
reported as successful.54,174,177,178 Finally, despite efﬁcacy in
colitis management, TNF-a inhibitors should be avoided given
the high rate of complicating deadly infections (2 deaths out of 5
inﬂiximab-treated patients with CGD179).
Immune reconstitution
In CGD, HSCT has been shown to be curative in terms of
both the recurrent infections and the multiorgan granulomatous
pathology.180 However, using full myeloablative conditioning,
patients with peritransplant comorbidities including colitis had
increased mortality,180 bringing up controversy as to the optimal
timing and conditioning for transplant. More recently, reduced-
intensity conditioning using high-dose ﬂudarabine, serotherapy,
and low-dose busulfan in high-risk CGD was shown to be both
safe and effective (89% event-free survival at 21-month follow-
up181). Because this study included 33% of patients with active
peritransplant colitis, the data suggest that this reduced-intensity
conditioning HSCT can be considered in severe CGD cases
complicated by IBD.
Finally, although directed immunosuppression in IPEX can
help to reduce the burden of multiorgan inﬂammatory pathol-
ogy, HSCT is the only deﬁnitive treatment. Improved outcomes
are seen with earlier age and fewer comorbidities at time of
transplant and with the use of reduced-toxicity conditioning
regimens.182-188 Even in the case of partial donor chimerism,
clinical disease remission has been reported, coinciding with the
presence of full donor Treg cells.184,186 The selective advantage
of wild-type Treg cells is consistent with the underlying patho-
physiology of IPEX and may dictate Treg-cell sparing therapies
for graft-versus-host disease in the posttransplant period.159
CONCLUSIONS
Autoimmune and inﬂammatory diseases can greatly compli-
cate the care of patients with PID. Treatment strategies in PID
should be targeted not only to the clinical spectrum of autoim-
munity (cytopenias, rheumatologic disease, and/or GI disease)
but also to the underlying molecular cause of immune dysre-
gulation (B-cell, T-cell, and/or innate immune pathology). As we
advance our understanding of mechanisms that mediate auto-
immunity in PID, we inherently improve the care of our patients
with PID and broaden our basic understanding of autoimmune
and inﬂammatory disease.
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